JP7846113B2 - 置換ピペリジノ化合物及び関連する治療方法 - Google Patents
置換ピペリジノ化合物及び関連する治療方法Info
- Publication number
- JP7846113B2 JP7846113B2 JP2023534354A JP2023534354A JP7846113B2 JP 7846113 B2 JP7846113 B2 JP 7846113B2 JP 2023534354 A JP2023534354 A JP 2023534354A JP 2023534354 A JP2023534354 A JP 2023534354A JP 7846113 B2 JP7846113 B2 JP 7846113B2
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- halogens
- alkyl
- heteroaryl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128511P | 2020-12-21 | 2020-12-21 | |
| US63/128,511 | 2020-12-21 | ||
| PCT/US2021/064484 WO2022140317A1 (en) | 2020-12-21 | 2021-12-21 | Substituted piperidino compounds and related methods of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554282A JP2023554282A (ja) | 2023-12-27 |
| JP2023554282A5 JP2023554282A5 (cg-RX-API-DMAC10.html) | 2024-12-20 |
| JP7846113B2 true JP7846113B2 (ja) | 2026-04-14 |
Family
ID=80218521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534354A Active JP7846113B2 (ja) | 2020-12-21 | 2021-12-21 | 置換ピペリジノ化合物及び関連する治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11760747B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4263506B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7846113B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN116670124A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021409664A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3172862A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3012114T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022140317A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| JP7833486B2 (ja) * | 2021-05-26 | 2026-03-19 | アルカーメス，インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| WO2023249871A1 (en) * | 2022-06-21 | 2023-12-28 | Alkermes, Inc. | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment |
| WO2024141660A2 (en) | 2022-12-30 | 2024-07-04 | Aexon Labs. Inc. | Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases |
| TW202502342A (zh) * | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| TW202547460A (zh) * | 2024-04-04 | 2025-12-16 | 日商橘生藥品工業股份有限公司 | 取代磺醯胺化合物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523540A (ja) | 2007-04-03 | 2010-07-15 | ファイザー・インク | スルホンアミドおよびその医薬組成物 |
| JP2014523851A (ja) | 2011-04-05 | 2014-09-18 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
| JP2019504098A (ja) | 2016-02-04 | 2019-02-14 | 武田薬品工業株式会社 | 置換ピペリジン化合物およびその用途 |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| WO1999023114A1 (en) | 1997-10-31 | 1999-05-14 | Biomira Inc. | Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression |
| AU2903999A (en) | 1998-03-12 | 1999-09-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| CA2324205A1 (en) | 1998-04-03 | 1999-10-14 | University Of Washington | Circularly permuted biotin binding proteins |
| EP1151012A4 (en) | 1998-11-19 | 2003-01-08 | Smithkline Beecham Corp | ANTAGONIST ANTIBODIES OF RHAMM |
| US6428985B1 (en) | 1998-12-02 | 2002-08-06 | The Regents Of The University Of Michigan | Immunosuppressive structural definition of IL-10 |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| AU2001231532A1 (en) | 2000-02-11 | 2001-08-20 | Maxygen Aps | Improved interleukin 10 |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| SI1724284T1 (sl) | 2000-12-07 | 2009-12-31 | Lilly Co Eli | Glp-1 fuzijski proteini |
| HUP0400698A3 (en) | 2001-02-06 | 2006-01-30 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| WO2003010201A2 (en) | 2001-07-20 | 2003-02-06 | Absorber, Ab | Blood group antigen fusion polypeptides and methods of use thereof |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| US7638323B2 (en) | 2002-08-09 | 2009-12-29 | Recopharma Ab | Fusion proteins and methods of producing same |
| WO2004044006A1 (en) | 2002-11-14 | 2004-05-27 | Maxygen, Inc. | Conjugates of interleukin-10 and polymers |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| SI1624891T2 (sl) | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| US7696322B2 (en) | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| US20150071948A1 (en) | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| WO2005034863A2 (en) | 2003-10-03 | 2005-04-21 | Jarikuma Corporation | Countermeasures against malaria |
| WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| US8454963B2 (en) | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
| US7576183B2 (en) | 2003-12-24 | 2009-08-18 | Los Alamos National Security, Llc | Structure-based receptor MIMICS targeted against bacterial superantigen toxins |
| US7851463B2 (en) | 2004-10-14 | 2010-12-14 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| CA2588449A1 (en) | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
| KR20080013853A (ko) | 2005-02-23 | 2008-02-13 | 사이케노믹스, 인코퍼레이티드 | 복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도 |
| US7829679B2 (en) | 2005-08-12 | 2010-11-09 | Riken | Mucin-type glycoprotein and use thereof |
| JPWO2007063907A1 (ja) | 2005-11-30 | 2009-05-07 | 塩野義製薬株式会社 | ペプチド糖鎖付加体およびそれを有効成分とする医薬 |
| ATE437889T1 (de) | 2005-12-02 | 2009-08-15 | Apceth Gmbh & Co Kg | Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration |
| WO2008140595A2 (en) | 2006-12-01 | 2008-11-20 | President And Fellows Of Harvard College | Synthetic trivalent haptens, complexes thereof, and uses therefor |
| WO2008133928A2 (en) | 2007-04-27 | 2008-11-06 | The Gi Company, Inc. | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders |
| CA2695374A1 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| WO2009076236A2 (en) | 2007-12-06 | 2009-06-18 | Pain Therapeutics, Inc. | Micronized opioid compositions, formulations and dosage forms and methods of making same |
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| BRPI0914889A2 (pt) | 2008-06-17 | 2015-11-24 | Otsuka Chemical Co Ltd | peptídeo glp-1 adicionado de cadeia oligossacarídica |
| RU2518471C2 (ru) | 2008-08-14 | 2014-06-10 | Тиботек Фармасьютикалз | Макроциклические индольные производные, применимые в качестве ингибиторов вируса гепатита с |
| JP2012525415A (ja) | 2009-05-01 | 2012-10-22 | オプソテツク・コーポレイシヨン | 眼科疾患を処置または予防するための方法 |
| AU2010264095B2 (en) | 2009-06-26 | 2013-07-11 | Biogen Ma Inc. | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
| KR20120107122A (ko) | 2009-12-22 | 2012-09-28 | 노파르티스 아게 | 치료법에서 사용하기 위한 ４가 ｃｄ４７―항체 불변 영역 융합 단백질 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
| CN101962413B (zh) | 2010-09-21 | 2013-03-13 | 中国科学技术大学 | 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用 |
| KR101333958B1 (ko) | 2010-10-20 | 2013-11-27 | 주식회사 한독 | 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질 |
| EP2457579A1 (en) | 2010-11-26 | 2012-05-30 | Technische Universität Dresden | Covalently linked interleukin -10 |
| TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| EP2836485B1 (en) | 2012-03-17 | 2018-01-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| EP2851429B1 (en) | 2012-05-18 | 2019-07-24 | Adda Biotech Inc. | Protein and protein conjugate for diabetes treatment, and applications thereof |
| US9156897B2 (en) | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| CN104640561A (zh) | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
| US9346872B2 (en) | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| WO2014151910A1 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Heterodimeric bispecific antibodies |
| JP2016526014A (ja) | 2013-04-24 | 2016-09-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | インターロイキン−１０組成物及びその使用 |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| US20160250224A1 (en) | 2013-09-24 | 2016-09-01 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| WO2015073707A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| SG11201604639YA (en) | 2013-12-12 | 2016-07-28 | Univ Tsukuba | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| BR112016016658A2 (pt) | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| JP6552117B2 (ja) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | 敗血症の予防治療剤 |
| JP6715239B2 (ja) | 2014-09-11 | 2020-07-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| WO2016101119A1 (en) | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Fused heteroaryl derivatives as orexin receptor antagonists |
| WO2016133160A1 (ja) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| CA2989146A1 (en) | 2015-06-12 | 2016-12-15 | Board Of Regents, The University Of Texas System | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof |
| DK3310784T3 (da) | 2015-06-17 | 2020-11-09 | Pfizer | Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| AU2016315878A1 (en) | 2015-09-03 | 2018-03-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10377770B2 (en) | 2015-12-18 | 2019-08-13 | Novartis Ag | Tricyclic compounds and compositions as kinase inhibitors |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| US10428023B2 (en) | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| CN111132975B (zh) | 2017-09-28 | 2023-05-23 | 勃林格殷格翰国际有限公司 | N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺 |
| JP7170996B2 (ja) | 2017-12-12 | 2022-11-15 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
| WO2019191327A1 (en) | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas System | Ox2r compounds |
| US11655241B2 (en) | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| EP3816154B1 (en) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| PE20211700A1 (es) | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| JP2022547604A (ja) | 2019-09-13 | 2022-11-14 | 武田薬品工業株式会社 | 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 |
| CN110642684B (zh) | 2019-10-15 | 2022-07-26 | 天津师范大学 | 一类基于联苯芳烃的大环和笼状分子及衍生化合物及其合成方法与应用 |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| WO2021106975A1 (ja) | 2019-11-27 | 2021-06-03 | 武田薬品工業株式会社 | 複素環化合物 |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| CA3167050A1 (en) | 2020-01-10 | 2021-07-15 | Takeda Pharmaceutical Company Limited | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
| CN119235864A (zh) | 2020-07-17 | 2025-01-03 | 卫材R&D管理有限公司 | 取代的哌啶化合物及其用途 |
| WO2022040058A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Cyclopentapyrrole orexin receptor agonists |
| US20230365533A1 (en) | 2020-08-18 | 2023-11-16 | Merck Sharp & Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists |
| CN116635393A (zh) | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| JP2022064180A (ja) | 2020-10-13 | 2022-04-25 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2022094012A1 (en) | 2020-11-02 | 2022-05-05 | Merck Sharp & Dohme Corp. | Macrocyclic urea orexin receptor agonists |
| EP4247801A4 (en) | 2020-11-23 | 2024-10-30 | Merck Sharp & Dohme LLC | 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS |
| US12552767B2 (en) | 2020-12-03 | 2026-02-17 | Merck Sharp & Dohme Llc | 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| US12692262B2 (en) | 2020-12-16 | 2026-07-28 | Merck Sharp & Dohme Llc | Substituted ureas as orexin receptor agonists |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7860139B2 (ja) | 2021-03-03 | 2026-05-15 | リサーチ トライアングル インスティテュート | オレキシン受容体アゴニストとしてのアリールスルホンアミド |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| MX2023012971A (es) | 2021-05-03 | 2024-01-16 | Jazz Pharmaceuticals Ireland Ltd | Agonistas del receptor de orexina y sus usos. |
| JPWO2022250108A1 (cg-RX-API-DMAC10.html) | 2021-05-26 | 2022-12-01 | ||
| EP4359387A1 (en) | 2021-06-25 | 2024-05-01 | Jazz Pharmaceuticals Ireland Limited | Sulfonamide orexin receptor agonists and uses thereof |
| WO2023017180A1 (en) | 2021-08-13 | 2023-02-16 | Orexia Therapeutics Limited | Peptide derivatives and related uses as orexin agonists |
-
2021
- 2021-12-20 US US17/556,295 patent/US11760747B2/en active Active
- 2021-12-21 ES ES21854780T patent/ES3012114T3/es active Active
- 2021-12-21 EP EP21854780.0A patent/EP4263506B1/en active Active
- 2021-12-21 CN CN202180080063.0A patent/CN116670124A/zh active Pending
- 2021-12-21 JP JP2023534354A patent/JP7846113B2/ja active Active
- 2021-12-21 WO PCT/US2021/064484 patent/WO2022140317A1/en not_active Ceased
- 2021-12-21 CA CA3172862A patent/CA3172862A1/en active Pending
- 2021-12-21 AU AU2021409664A patent/AU2021409664A1/en active Pending
-
2023
- 2023-08-04 US US18/230,329 patent/US12441710B2/en active Active
-
2025
- 2025-09-22 US US19/335,265 patent/US20260078106A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523540A (ja) | 2007-04-03 | 2010-07-15 | ファイザー・インク | スルホンアミドおよびその医薬組成物 |
| JP2014523851A (ja) | 2011-04-05 | 2014-09-18 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
| JP2019504098A (ja) | 2016-02-04 | 2019-02-14 | 武田薬品工業株式会社 | 置換ピペリジン化合物およびその用途 |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260078106A1 (en) | 2026-03-19 |
| AU2021409664A9 (en) | 2024-10-24 |
| JP2023554282A (ja) | 2023-12-27 |
| CN116670124A (zh) | 2023-08-29 |
| ES3012114T3 (en) | 2025-04-08 |
| CA3172862A1 (en) | 2022-06-30 |
| US20240076283A1 (en) | 2024-03-07 |
| US20220194926A1 (en) | 2022-06-23 |
| EP4263506B1 (en) | 2025-02-05 |
| AU2021409664A1 (en) | 2023-05-25 |
| EP4263506C0 (en) | 2025-02-05 |
| EP4263506A1 (en) | 2023-10-25 |
| US11760747B2 (en) | 2023-09-19 |
| US12441710B2 (en) | 2025-10-14 |
| WO2022140317A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501641A (ja) | 置換大環状化合物及び関連する治療方法 | |
| EP4329877B1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| EP4263506B1 (en) | Substituted piperidino compounds and related methods of treatment | |
| US9133122B2 (en) | Amide compounds, compositions and uses thereof | |
| DE60315615T2 (de) | Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen | |
| IL320038A (en) | Substituted macrocyclic compounds compositions comprising same and uses thereof | |
| US20240182491A1 (en) | Substituted fused bicyclic macrocyclic compounds and related methods of treatment | |
| JP7833486B2 (ja) | 置換されるカルバメート大環状化合物および関連のある治療方法 | |
| EP4543446A1 (en) | Substituted fused bicyclic compounds and related methods of treatment | |
| CN119730843A (zh) | 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法 | |
| JP2025521508A (ja) | 置換ピロリジニル及びピペリジニル化合物並びに関連する治療方法 | |
| HK40099265A (en) | Substituted piperidino compounds and related methods of treatment | |
| HK40099265B (en) | Substituted piperidino compounds and related methods of treatment | |
| HK40108225A (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| HK40108225B (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| HK40106635B (en) | Substituted carbamate macrocyclic compounds and related methods of treatment | |
| HK40106635A (en) | Substituted carbamate macrocyclic compounds and related methods of treatment | |
| JP2025521504A (ja) | 置換縮合二環式化合物および関連する治療方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241212 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250918 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250925 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251222 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260317 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260402 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7846113 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |